Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Florence Hsu

Allergy & Immunology North Haven, CT Medical Doctor

NPI 1205894607 CMS profile 327212

6 Devine St Ste 2B, North Haven, CT 06473

Open in the dashboard

General payments

$84,084

90 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$44,895 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Florence Hsu of North Haven, CT is reported in the CMS Open Payments database as having received $84,084 across 90 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $44,895 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,866 12
2024 General $12,515 12
2023 General $4,997 11
2022 General $12,345 11
2021 General $11,269 8
2020 General $12,566 10
2019 General $11,527 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Florence Hsu
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Florence Hsu were reported at $18,866. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Florence Hsu Allergy & Immunology median Middle half National median
2019 $11,527 $378 $115–$1,178 $163
2020 $12,566 $303 $75–$1,581 $114
2021 $11,269 $407 $122–$1,475 $132
2022 $12,345 $357 $120–$1,340 $149
2023 $4,997 $445 $124–$1,536 $160
2024 $12,515 $541 $129–$1,763 $164
2025 $18,866 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $35,513 39 payments
  2. Pharming Healthcare, Inc. $26,400 24 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $8,463 8 payments
  4. BioCryst Pharmaceuticals, Inc. $6,049 9 payments
  5. Amgen Inc. $3,939 4 payments
  6. BioCryst US Sales Co., LLC $1,375 1 payment
  7. Blueprint Medicines Corporation $1,260 1 payment
  8. Shire North American Group Inc $900 1 payment
  9. Regeneron Healthcare Solutions, Inc. $90 1 payment
  10. Genentech USA, Inc. $61 1 payment
  11. Other $35 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,902 25 payments
  2. Honoraria $28,565 18 payments
  3. Consulting Fee $20,573 10 payments
  4. Travel and Lodging $3,756 13 payments
  5. Food and Beverage $1,240 20 payments
  6. Education $49 4 payments
Products named General payments · program years 2019–2025
  1. RUCONEST $26,400 24 payments
  2. Andembry $14,419 10 payments
  3. Orladeyo $4,035 2 payments
  4. TEZSPIRE $3,884 3 payments
  5. Haegarda $3,487 5 payments
  6. TAKHZYRO $2,955 3 payments
  7. CUVITRU $2,674 3 payments
  8. AYVAKIT $1,260 1 payment
  9. CINRYZE $1,046 1 payment
  10. HYQVIA $900 1 payment
  11. Other $125 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

162

Median for Allergy/ Immunology: 449

Drug cost

$3,003,131

Median for Allergy/ Immunology: $169,700

Branded share of claims

52.5%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Berinert C1 Esterase Inhibitor Brand 48 $2,307,372
Haegarda C1 Esterase Inhibitor Brand 22 $634,304
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 15 $60,874
Oxycodone Hcl Generic 61 $452
Hydroxyzine Hcl Generic 16 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$4,644

Medicare's payments for the services billed

Medicare patients

36

Average age 69

Services billed

114

25 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 50%
COPD 33%
Osteoporosis 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record